

ULACNet Annual Meeting 2020

Session Five: ULACNet 'Think Tank'

Breakout Rooms Instructions

- ❖ Participants will have the opportunity to discuss both framing questions (one for each session).
- ❖ Each breakout room will have pre-assigned moderators and a notetaker.
- ❖ Participants, moderators, and notetakers will be moved to a breakout room by the meeting host at the beginning of the think tank session.
- ❖ Participants and notetakers will remain in their pre-assigned room during both sessions.
- ❖ The moderators move between the rooms at the halfway mark.
- ❖ Participants, moderators, and notetakers will be moved back to the main room by the meeting host.



Participants: ●

Moderators: ● ● ● ●

Notetakers: ● ●

Breakout Rooms Set Up

Session #1
2:00pm – 2:30pm




Participants: ●

Moderators: ● ● ● ●

Notetakers: ● ●

A legend defining the symbols used in the room diagrams. It shows a grey circle for 'Participants', four circles with different diagonal stripes (red, blue, green, purple) for 'Moderators', and two solid circles (teal and purple) for 'Notetakers'.

Session #2
2:30pm – 3:00pm



NOTE: Only the moderators will switch rooms between the sessions. All others will remain in their assigned breakout room.

Moderators

Topic A: SWOT Analysis



Ann Duerr
Fred Hutchinson Cancer
Research Center



Joel Palefsky
University of California
San Francisco

Topic B: Recruitment, Retention & Adherence



Betania Allen-Leigh
National Institute of
Public Health Mexico



Maggie House
National Cancer
Institute

Topic A Framing Question

What are the potential SWOTs that may influence the success of ULACNet-301 (OPTIMO)?

- **Strengths** [*Internal*: e.g., well-prepared, dedicated staff, etc.]
- **Weaknesses** [*Internal*: e.g., too few staff, infrastructure support, etc.]
- **Opportunities** [*External*: e.g., collaborative research efforts, etc.]
- **Threats** [*External*: Local regulatory issues, drug acquisition issues, mistrust of researchers by community, broad access to info about clinical trials, etc.]
- Similar SWOTs in other studies in ULACNet

Topic B Framing Question

What are some recruitment, retention, and adherence (RR&A) lessons learned **from past studies** that may be used to influence RR&A for ULACNet studies?

- **Problems** related to recruitment, retention, and adherence
- **Strategies** to overcome problems or barriers

Thematic Areas and Target Populations of Proposed ULACNet Clinical Trials

CAMPO Consortium	ROCCHHA Consortium	Colaboración Evita
<i>Mexico, Puerto Rico, US</i>	<i>Brazil, Mexico, Puerto Rico, US</i>	<i>Peru, Dominican Republic, Brazil, US</i>
Cervical and Anal Cancer Screening/Triage of HIV+ women & men	HPV vaccine in HIV+ men & transgender women	HPV vaccine in HIV+ children
Topical treatment in HIV+ women & men	Cervical Cancer Screening/Triage of HIV+ women	Cervical Cancer Screening/Triage of HIV+ women
Therapeutic HPV vaccine in HIV+ women & men	Therapeutic HPV vaccine in HIV+ women	Topical treatment in HIV+ women

HPV prophylactic vaccines
Anogenital Screening/Triage
Novel Precancer treatments



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol